Heart Test Laboratories (HSCS) Stock Price, News & Analysis

Company Overview

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Key Stats

• Today's Range: $3.66 to $4.08
• 50-Day Range: $3.22 to $3.99
• 52-Week Range: $2.36 to $18.50
• Volume: 19,548 shs
• Average Volume: 18,195 shs
• Market Capitalization: $3.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.50
• Consensus Rating: Buy

Heart Test Laboratories Stock Analysis - MarketRank™

Heart Test Laboratories scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Heart Test Laboratories has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Heart Test Laboratories has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Heart Test Laboratories are expected to grow in the coming year, from ($10.01) to ($8.80) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Heart Test Laboratories is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Heart Test Laboratories is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Heart Test Laboratories has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.05% of the float of Heart Test Laboratories has been sold short.

Short Interest Ratio / Days to Cover

Heart Test Laboratories has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Heart Test Laboratories has recently decreased by 13.51%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Heart Test Laboratories does not currently pay a dividend.

Dividend Growth

Heart Test Laboratories does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.05% of the float of Heart Test Laboratories has been sold short.

Short Interest Ratio / Days to Cover

Heart Test Laboratories has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Heart Test Laboratories has recently decreased by 13.51%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

MarketBeat Follows

Only 1 people have added Heart Test Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Heart Test Laboratories insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.80% of the stock of Heart Test Laboratories is held by insiders.

Percentage Held by Institutions

Only 17.24% of the stock of Heart Test Laboratories is held by institutions.

HSCS Stock Analysis - Frequently Asked Questions

How have HSCS shares performed this year?

Heart Test Laboratories' stock was trading at $3.82 at the beginning of the year. Since then, HSCS stock has decreased by 3.4% and is now trading at $3.69.
View the best growth stocks for 2025 here.

How were Heart Test Laboratories' earnings last quarter?

Heart Test Laboratories, Inc. (NASDAQ:HSCS) posted its earnings results on Monday, December, 16th. The company reported ($2.27) EPS for the quarter, beating analysts' consensus estimates of ($2.30) by $0.03.

When did Heart Test Laboratories' stock split?

Heart Test Laboratories shares reverse split before market open on Friday, May 17th 2024. The 1-100 reverse split was announced on Friday, May 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

When did Heart Test Laboratories IPO?

Heart Test Laboratories (HSCS) raised $9 million in an initial public offering (IPO) on Wednesday, June 15th 2022. The company issued 1,800,000 shares at a price of $4.50-$5.50 per share. The Benchmark Company acted as the underwriter for the IPO.

How do I buy shares of Heart Test Laboratories?

Shares of HSCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Heart Test Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Heart Test Laboratories investors own include Meta Platforms (META), Cardio Diagnostics (CDIO), Invesco QQQ (QQQ), RH (RH), Exxon Mobil (XOM), Amarin (AMRN) and American Express (AXP).

Company Calendar

• Last Earnings: 12/16/2024
• Today: 2/22/2025
• Next Earnings (Estimated): 3/13/2025
• Fiscal Year End: 4/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical appliances & supplies
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:HSCS
• CUSIP: N/A
• CIK: 1468492
• Web: heartsciences.com
• Phone: 682-237-7781
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $13.50
• High Stock Price Target: $15.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +265.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($7.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-6,610,000.00
• Net Margins: N/A
• Pretax Margin: -50,833.34%
• Return on Equity: -117.76%
• Return on Assets: -84.09%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 1.72
• Quick Ratio: 1.52

Sales & Book Value

• Annual Sales: $14,700.00
• Price / Sales: 246.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.16 per share
• Price / Book: 0.33

Miscellaneous

• Outstanding Shares: 980,000
• Free Float: 962,000
• Market Cap: $3.62 million
• Optionable: Not Optionable
• Beta: 2.88